A Phase I/IIa, Open-label Investigation of the Safety and Clinical Effects of NTCELL [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease
Latest Information Update: 10 Jun 2020
At a glance
- Drugs Choroid plexus cell replacement therapy (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man
- Sponsors Living Cell Technologies
- 20 Feb 2020 Planned End Date changed from 29 Nov 2019 to 4 Mar 2020.
- 12 Sep 2019 Planned End Date changed from 29 Apr 2019 to 29 Nov 2019.
- 21 Nov 2018 Planned End Date changed from 1 Jun 2015 to 29 Apr 2019.